Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo —— Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior

BenzingaJun 17 15:04

Research by hutchmed (china) (00013.HK) shows that solcitinib has the potential to become a treatment option for immune thrombocytopenia patients.

Hutchmed (China) (00013.HK) announced that the results of the ESLIM-01 phase III study of Solitinib (Solveplenib, HMPL-523) for adult primary immune thrombocytopenia patients have been published in The Lancet Haematology. Additional details and subgroup results of the study were also presented in the form of an oral report and two posters at the European Hematology Association (EHA) 2024 Annual Meeting on June 14. Solitinib is used to treat hematological malignancies and

AASTOCKSJun 17 08:55

Hutchmed (China) announced that the results of the phase III ESLIM-01 study were published in The Lancet Haematology.

On June 17th, HutchMed (China) (00013.HK) announced that the results of the ESLIM-01 Phase III study of Sovleplenib (HMPL-523) for adults with primary immune thrombocytopenia were published in The Lancet Haematology. Additional details and subgroup results of this study were also presented in the form of an oral report and two posters at the European Hematology Association (EHA) 2024 annual meeting on June 14th. Sovleplenib is a type of

Gelonghui FinanceJun 17 08:06

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that results from ESLIM-01, HUTCHMED's Phase III trial of sovleplenib (HMPL-523), in adult patients with primary immune thrombocytopenia ("ITP") in China, were published in The Lancet Haematology.

GlobeNewswireJun 17 08:00

Open source securities: first-time buy rating for hutchmed (china) (00013), entering the global harvest period in the solid tumor field.

According to the research report released by Kaiyuan Securities, bullish-rated Hutchmed (China) for the first time, expecting a net income attributable to shareholders of -648 million/18 million/1.131 billion yuan from 2024 to 2026. Fruquintinib has been approved for marketing in the United States in 2023 and is commercially sold overseas by Takeda Pharmaceutical. Multiple indications of several products in the pipeline are expected to be gradually approved in the global market in the coming years, and the company has entered the global harvest period. The bank is bullish on the company's long-term development. The pipeline is calculated based on the already approved and expected pipeline.

Zhitong FinanceJun 14 15:17

HK stocks abnormal | Hutchmed (China) Medicine (00013) rose more than 5%. The company recently launched the HMPL-506 phase I clinical trial for hematologic malignancies.

Hutchmed (China) (00013) rose more than 5%, as of press time, up 5.11%, reported HKD 29.85, with a turnover of HKD 33.2161 million.

Zhitong FinanceJun 13 11:14